Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE: Ibandronate vs Zoledronate in Multiple Myeloma
NCT02739594Phase 3Terminated
- Sponsor
- Roche
- Start
- Feb 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibandronate in multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) at 92 weeks. Started Feb 2006; status: terminated.
02
Drugs
ibandronate
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02739594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739594.